The CRO Industry: How Contract Research Organizations Run Clinical Trials
Clinical trials do not run themselves. Behind every study sits an ecosystem of sponsors, contract research organizations, trial sites, technology vendors, and regulators. It is a multi-billion dollar industry that employs hundreds of thousands of people worldwide. Understanding who does what, and where the money flows, explains a lot about how new treatments reach patients.
What a CRO actually does
A contract research organization, or CRO, is a company that pharmaceutical, biotechnology, and medical device sponsors hire to manage some or all of their clinical trials. CROs supply the expertise and infrastructure sponsors may not have in-house, from study design and site selection to data management and regulatory submissions.
The service list is long. Clinical trial management covers selecting sites, monitoring enrollment, and ensuring protocol compliance. Data management and biostatistics covers case report forms, databases, data cleaning, and statistical analysis. Medical writers produce protocols, informed consent forms, clinical study reports, and regulatory submissions. Regulatory affairs specialists prepare IND applications, interact with agencies like the FDA and EMA, and manage ethics committee submissions. Central labs process biological samples, and specialized providers handle imaging, cardiac safety, and patient recruitment.
A market measured in the tens of billions
The CRO industry has grown for thirty years as drug development became more complex and more global. The video values the global CRO market at roughly $60 billion in 2023, growing 8 to 10% a year. Independent market research lands in the same neighborhood: one analysis values the market at about USD 69.56 billion in 2025 and projects it to reach roughly USD 134 billion by 2035 (Precedence Research: CRO market). North America holds the largest share, around 45%, followed by Europe, with Asia Pacific the fastest-growing region.
A handful of large players dominate. IQVIA, formed from the merger of Quintiles and IMS Health, is the largest, with annual revenue over $15 billion (IQVIA). LabCorp's Covance division, ICON, Syneos Health, PPD (now part of Thermo Fisher), and Charles River Laboratories follow. Together the top ten control about 60% of the market. Below them sit hundreds of smaller specialty CROs focused on specific therapeutic areas, regions, or services.
A three-way partnership
The relationship between sponsor, CRO, and site is the engine of the industry. The sponsor owns the drug and the trial, provides funding, and sets strategy. The CRO runs operations: site selection, monitoring, data management, and regulatory submissions. The site recruits patients, administers treatment, and collects data. The incentives differ. Sponsors want speed and quality. CROs want to deliver on budget and keep clients. Sites want fair reimbursement and manageable workloads.
Sponsors outsource for concrete reasons. Cost efficiency, because CROs achieve economies of scale a single sponsor cannot. Access to global sites, because large CROs have relationships with thousands of sites in dozens of countries. Expertise across every specialty from regulatory affairs to biostatistics. Flexibility to scale up or down without permanent staff. And speed, because experienced CROs start trials faster and keep them on track.
Trends reshaping the industry
Consolidation is the defining market trend. Large CROs keep acquiring smaller ones to offer full-service solutions and expand geographic reach. The Quintiles-IMS merger and Thermo Fisher's purchase of PPD are the marquee examples. Technology is the other driver. Electronic data capture has replaced paper case report forms. Risk-based monitoring uses analytics to focus oversight on the highest-risk sites and data points, an approach the FDA explicitly endorses in its guidance on monitoring clinical investigations (FDA guidance: oversight of clinical investigations, risk-based monitoring). Artificial intelligence is being applied to find eligible patients in electronic health records, predict timelines, and flag data anomalies. Clinical trial management systems centralize planning and tracking. Industry initiatives like TransCelerate push shared standards across sponsors and CROs (TransCelerate Biopharma).
The pressure points
The industry has real problems. There is a talent shortage: experienced clinical research professionals, from clinical research associates to biostatisticians, are in high demand, and organizations like the Association of Clinical Research Professionals exist partly to train and certify them (ACRP). Costs keep rising for sites, investigator fees, and technology. Regulations keep evolving in every country. Enrollment remains the chronic bottleneck, with up to 80% of trials failing to enroll on time. And sponsors are squeezing CRO margins while value-based pricing creates uncertainty about future R&D budgets.
The bottom line
CROs are the backbone of modern clinical research. They provide the expertise, infrastructure, and global reach most sponsors cannot match in-house, and they do it inside a market worth more than $60 billion and growing. The industry is consolidating, digitizing, and pushing toward patient-centric, decentralized trial models. The challenges are real: talent, cost, enrollment, and pricing pressure. But the fundamental driver is strong. Drug development is becoming more complex, more globalized, and more dependent on specialized partners. The CRO industry is not just a service provider. It is the engine that turns discoveries into approved treatments.
This article is based on the Clarity Clinical Solutions video "CRO Market & Industry - Clinical trials do not run themselves." Watch it here: CRO Market & Industry - Clinical trials do not run themselves
References
- Clarity Clinical Solutions video — the framework for this article: CRO services, market size, major players, trends, and challenges. https://www.youtube.com/watch?v=L9284Vv8Bjg
- Precedence Research — Contract research organization market size and forecast. https://www.precedenceresearch.com/contract-research-organization-market
- IQVIA — company site; the largest global CRO. https://www.iqvia.com/
- FDA — Guidance on risk-based monitoring of clinical investigations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring
- TransCelerate Biopharma — industry collaboration on shared trial standards. https://www.transceleratebiopharmainc.com/
- ACRP — Association of Clinical Research Professionals. https://acrpnet.org/